Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 160

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects

Open access
Näslund, Erik, King, N., Mansten, S., Adner, N., Holst, J. J., Gutniak, M., Hellström, P. M. · 2004 · British Journal of Nutrition

Abstract

Recombinant glucagon-like peptide-1 (7–36)amide (rGLP-1) was recently shown to cause significant weight loss in type 2 diabetics when administered for 6 weeks as a continuous subcutaneous infusion. The mechanisms responsible for the weight loss are not clarified. In the present study, rGLP-1 was given for 5d by prandial subcutaneous injections (PSI) (76nmol 30min before meals, four times daily; a total of 302·4nmol/24h) or by continuous subcutaneous infusion (CSI) (12·7nmol/h; a total of 304·8nmol/24h). This was performed in nineteen healthy obese subjects (mean age 44·2 (sem 2·5) years; BMI 39·0 (sem 1·2)kg/m 2) in a prospective randomised, double-blind, placebo-controlled, cross-over study. Compared with the placebo, rGLP-1 administered as PSI and by CSI generated a 15% reduction in mean food intake per meal (P=0·02) after 5d treatment. A weight loss of 0·55 (sem 0·2) kg (P<0·05) was registered after 5d with PSI of rGLP-1. Gastric emptying rate was reduced during both PSI (P<0·001) and CSI (P<0·05) treatment, but more rapidly and to a greater extent with PSI of rGLP-1. To conclude, a 5d treatment of rGLP-1 at high doses by PSI, but not CSI, promptly slowed gastric emptying as a probable mechanism of action of increased satiety, decreased hunger and, hence, reduced food intake with an ensuing weight loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1079/bjn20031064

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 24

  1. 10.2337/diacare.22.7.1137 · DOI · Paper page
  2. 10.1046/j.1365-2362.1997.1490691.x · DOI
  3. 10.2337/diabetes.47.4.530 · DOI
  4. 10.1002/cne.902340306 · DOI · Paper page
  5. 10.2337/diab.45.6.832 · DOI · Paper page
  6. Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am J Physiol, 273, E981
  7. 10.1093/ajcn/68.3.525 · DOI · Paper page
  8. 10.1016/0006-8993(89)90628-8 · DOI
  9. 10.1046/j.1365-2796.2001.00862.x · DOI
  10. 10.2337/diacare.17.9.1039 · DOI
  11. Edwards, 2001, Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers, Am J Physiol, 281, E155
  12. Barkeling, 1990, Effects of high-protein meal (meat) and a high-carbohydrate meal (vegetarian) on satiety measured by automated computerized monitoring on subsequent food intake, Int J Obes Relat Metab Disord, 14, 743
  13. 10.1007/BF00401846 · DOI · Paper page
  14. 10.2337/diab.43.4.535 · DOI · Paper page
  15. 10.1136/gut.44.1.81 · DOI · Paper page
  16. Gutzwiller, 1999, Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2, Am J Physiol, 276, R1541
  17. Näslund, 1999, GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans, Am J Physiol, 277, R910
  18. Grybäck, 2000, Nationwide standardisation and evaluation of scintigraphic gastric emptying: reference values and comparison between subgroups in a multicentre trial, Eur J Nucl Med, 27, 647, 10.1007/s002590050558 · DOI
  19. 10.1007/s001250050613 · DOI · Paper page
  20. 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
  21. 10.1172/JCI112855 · DOI · Paper page
  22. Larsen, 2001, Systemic administration of the long-acting GLP-1 analogue, NN2211, induces lasting and reversible loss of body obesity, Diabetologia, 43, A144
  23. Verdich, 2001, A meta-analysis of the effect of glucagon-like peptide-1 (7–36)amide on ad libitum food intake in humans, J Clin Endocrinol Metabol, 86, 4382
  24. 10.1080/003655200750023930 · DOI

Cited by

See all 160

Metadata

Authors
Näslund, E., King, N., Mansten, S., Adner, N., Holst, J. J., Gutniak, M., & Hellström, P. M.
Venue
British Journal of Nutrition
Published
2004-03
Volume
91
Issue
3
Pages
439-446
ISSN
  • 0007-1145 (ISSN-L)
  • 1475-2662
OpenAlex
W1568809670
Cited by
160
References
9
FWCI
4.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.